137 related articles for article (PubMed ID: 36796862)
1. Oncological outcomes among young women with non-epithelial ovarian cancer: the YOC-Care study (Young Ovarian Cancer - Care).
Minig L; Gracia Segovia M; Arencibia O; Zorrero C; Marti L; García Pineda V; Cespedes J; Niguez I; Gil-Ibanez B; Diaz-Feijoo B; Fidalgo S; Valencia I; Alonso-Gutierrez T; Gonzalez L; Veiga-Fernandez A; Chacon E; Negredo I; Azcona Sutil L; Gorostidi M; Zapardiel I;
Int J Gynecol Cancer; 2023 Jun; 33(6):915-921. PubMed ID: 36796862
[TBL] [Abstract][Full Text] [Related]
2. Prognostic factors in young women with epithelial ovarian cancer: the Young Ovarian Cancer-Care (YOC-Care) study.
Azcona L; Heras M; Arencibia O; Minig L; Marti L; Baciu A; Cespedes J; Niguez I; Gil-Ibanez B; Díaz-Feijoo B; Melero LM; Marcos Sanmartin J; Garcia-Villayzan J; Gomez B; Montesinos M; Herrero S; Gilabert-Estelles J; F Chereguini M; Gorostidi M; Zapardiel I;
Int J Gynecol Cancer; 2023 Dec; ():. PubMed ID: 38086566
[TBL] [Abstract][Full Text] [Related]
3. Adult ovarian granulosa cell tumors: analysis of outcomes and risk factors for recurrence.
Plett H; Ricciardi E; Vacaru V; Ramspott JP; Colombo N; Sehouli J; du Bois A; Garbi A; Richter R; Ataseven B; Aletti G; Braicu E; Heitz F; Portuesi R; Muallem MZ; Dagres T; Parma G; Roser E; Traut A; Multinu F; Harter P
Int J Gynecol Cancer; 2023 May; 33(5):734-740. PubMed ID: 36759002
[TBL] [Abstract][Full Text] [Related]
4. Clinical and pathologic features of patients with rare ovarian tumors: multi-center review of 167 patients by the anatolian society of medical oncology.
Bilici A; Inanc M; Ulas A; Akman T; Seker M; Babacan NA; Inal A; Bal O; Koral L; Sevinc A; Tufan G; Elkiran ET; Ustaalioglu BB; Yavuzsen T; Alkis N; Ozkan M; Gumus M
Asian Pac J Cancer Prev; 2014 Jan; 14(11):6493-9. PubMed ID: 24377556
[TBL] [Abstract][Full Text] [Related]
5. Sertoli-Leydig cell tumor: a clinicopathological analysis in a comprehensive, national cohort.
Bekker P; Miland-Samuelsen AR; Smerdel MP; Schnack TH; Lauszus FF; Karstensen SH
Int J Gynecol Cancer; 2023 Dec; 33(12):1921-1927. PubMed ID: 37907261
[TBL] [Abstract][Full Text] [Related]
6. Role of fertility-sparing surgery and further prognostic factors in borderline tumors of the ovary.
Westermann T; Karabeg E; Heitz F; Traut A; Plett H; Moubarak M; Welz J; Heikaus S; Lax S; du Bois A; Harter P
Int J Gynecol Cancer; 2024 Jun; 34(6):898-905. PubMed ID: 38627034
[TBL] [Abstract][Full Text] [Related]
7. Platinum-based adjuvant chemotherapy on moderate- and high-risk stage I and II epithelian ovarian cancer patients. Long-term single institution experience and literature review.
García-Sáenz JA; Custodio A; Casado A; Vidart JA; Coronado PJ; Martín M; López-Tarruella S; Puente J; Fernández C; Díaz-Rubio E
Clin Transl Oncol; 2011 Feb; 13(2):121-32. PubMed ID: 21324801
[TBL] [Abstract][Full Text] [Related]
8. The impact of clinicopathologic and surgical factors on relapse and pregnancy in young patients (≤40 years old) with borderline ovarian tumors.
Fang C; Zhao L; Chen X; Yu A; Xia L; Zhang P
BMC Cancer; 2018 Nov; 18(1):1147. PubMed ID: 30463533
[TBL] [Abstract][Full Text] [Related]
9. Neoadjuvant chemotherapy versus debulking surgery in advanced tubo-ovarian cancers: pooled analysis of individual patient data from the EORTC 55971 and CHORUS trials.
Vergote I; Coens C; Nankivell M; Kristensen GB; Parmar MKB; Ehlen T; Jayson GC; Johnson N; Swart AM; Verheijen R; McCluggage WG; Perren T; Panici PB; Kenter G; Casado A; Mendiola C; Stuart G; Reed NS; Kehoe S; ;
Lancet Oncol; 2018 Dec; 19(12):1680-1687. PubMed ID: 30413383
[TBL] [Abstract][Full Text] [Related]
10. Prognostic factors responsible for survival in sex cord stromal tumors of the ovary--an analysis of 376 women.
Zhang M; Cheung MK; Shin JY; Kapp DS; Husain A; Teng NN; Berek JS; Osann K; Chan JK
Gynecol Oncol; 2007 Feb; 104(2):396-400. PubMed ID: 17030354
[TBL] [Abstract][Full Text] [Related]
11. [Clinicopathologic and survival analysis of synchronous primary endometrial and ovarian cancer].
Wang Y; Yu M; Yang JX; Cao DY; Zhang Y; Shen K; You Y
Zhonghua Fu Chan Ke Za Zhi; 2018 Dec; 53(12):816-822. PubMed ID: 30585019
[No Abstract] [Full Text] [Related]
12. Contribution of lymph node staging method and prognostic factors in malignant ovarian sex cord-stromal tumors: A world wide database analysis.
Wang J; Li J; Chen R; Lu X
Eur J Surg Oncol; 2018 Jul; 44(7):1054-1061. PubMed ID: 29705285
[TBL] [Abstract][Full Text] [Related]
13. The Evaluation of Risk Factors Associated With Relapse and Recurrence of Borderline Ovarian Tumors With Long-Term Follow-up.
Sobiczewski P; Kupryjanczyk J; Michalski W; Śpiewankiewicz B
Int J Gynecol Cancer; 2016 Jul; 26(6):1053-61. PubMed ID: 27177283
[TBL] [Abstract][Full Text] [Related]
14. Results from a Monocentric Long-Term Analysis of 23 Patients with Ovarian Sertoli-Leydig Cell Tumors.
Gouy S; Arfi A; Maulard A; Pautier P; Bentivegna E; Leary A; Chargari C; Genestie C; Morice P
Oncologist; 2019 May; 24(5):702-709. PubMed ID: 30201740
[TBL] [Abstract][Full Text] [Related]
15. A detailed study of patients and tumor characteristics of epithelial ovarian cancer in Saudi women.
Al-Badawi IA; Munkarah AR; Tulbah A; Babic II; Al Husaini H; Ahmad S
Int J Gynecol Cancer; 2013 Mar; 23(3):456-60. PubMed ID: 23360812
[TBL] [Abstract][Full Text] [Related]
16. Overexpression of epithelial macrophage colony-stimulating factor (CSF-1) and CSF-1 receptor: a poor prognostic factor in epithelial ovarian cancer, contrasted with a protective effect of stromal CSF-1.
Chambers SK; Kacinski BM; Ivins CM; Carcangiu ML
Clin Cancer Res; 1997 Jun; 3(6):999-1007. PubMed ID: 9815777
[TBL] [Abstract][Full Text] [Related]
17. Prognostic significance of p53 expression in advanced-stage ovarian serous borderline tumors.
Gershenson DM; Deavers M; Diaz S; Tortolero-Luna G; Miller BE; Bast RC; Mills GB; Silva EG
Clin Cancer Res; 1999 Dec; 5(12):4053-8. PubMed ID: 10632339
[TBL] [Abstract][Full Text] [Related]
18. Minimally invasive surgical staging for early stage ovarian cancer: A long-term follow up.
Gallotta V; Jeong SY; Conte C; Trozzi R; Cappuccio S; Moroni R; Ferrandina G; Scambia G; Kim TJ; Fagotti A
Eur J Surg Oncol; 2021 Jul; 47(7):1698-1704. PubMed ID: 33573854
[TBL] [Abstract][Full Text] [Related]
19. Standard chemotherapy with or without bevacizumab for women with newly diagnosed ovarian cancer (ICON7): overall survival results of a phase 3 randomised trial.
Oza AM; Cook AD; Pfisterer J; Embleton A; Ledermann JA; Pujade-Lauraine E; Kristensen G; Carey MS; Beale P; Cervantes A; Park-Simon TW; Rustin G; Joly F; Mirza MR; Plante M; Quinn M; Poveda A; Jayson GC; Stark D; Swart AM; Farrelly L; Kaplan R; Parmar MK; Perren TJ;
Lancet Oncol; 2015 Aug; 16(8):928-36. PubMed ID: 26115797
[TBL] [Abstract][Full Text] [Related]
20. Prognostic relevance of uncommon ovarian histology in women with stage III/IV epithelial ovarian cancer.
Mackay HJ; Brady MF; Oza AM; Reuss A; Pujade-Lauraine E; Swart AM; Siddiqui N; Colombo N; Bookman MA; Pfisterer J; du Bois A;
Int J Gynecol Cancer; 2010 Aug; 20(6):945-52. PubMed ID: 20683400
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
